Navigation Links
Quintiles Selects invivodata as Primary Partner for ePRO Solutions; Collaboration to Enhance Value, Effectiveness and Speed in Drug Development
Date:1/18/2010

Please see this announcement regarding a new partnership among 2 leading service providers to the world-wide biopharmaceutical industry. Quintiles, the world's largest leading CRO has selected invivodata to be its preferred provider for electronic Patient Reported Outcomes (ePRO) solutions and services.

Research Triangle Park, N.C., and Pittsburgh, PA (Vocus) January 18, 2010 -- Quintiles, the world’s leading biopharmaceutical services company, and invivodata, inc., an industry leader in patient reported outcomes (PRO) solutions and services for global clinical research, today announced a collaboration agreement to transform the way Patient Reported Outcomes (PRO) are used in clinical research to speed drug development.

The collaborative arrangement connects invivodata’s PRO consulting, technology, and service solutions to the full suite of Quintiles’ clinical services, providing integrated processes and deliverables, It will reduce study complexity and cost as redundant services are removed throughout all phases of drug development.

“Regulators, especially the FDA, have increased the pressure on drug developers to focus on the patient’s perspective regarding drug effects, and Quintiles is working with customers to effectively manage this changing environment,” said Paula Brown Stafford, Executive Vice President, Integrated Clinical Services for Quintiles. “While the patient perspective can be obtained in various ways, real-time PRO data are common measures of drug efficacy, and ePRO is an accurate and reliable way to capture these data. Quintiles has led the CRO market place in providing electronic data capture services and ePRO is a logical extension of that leadership for our customers.

“Our collaboration with invivodata will provide handheld technology that drives high patient compliance and meets the needs of the ever-evolving regulatory guidelines. After a thorough evaluation, we found invivodata’s combination of science-based methodologies and innovative technology coupled with a collaborative approach to partnering in global support services to be a complement to Quintiles’ strategic vision for PRO,” added Stafford.

The agreement solidifies an ongoing collaborative effort between the companies, with invivodata providing its ePRO solutions in more than 20 joint studies to date.

“Quintiles’ vision for the implementation of eClinical solutions continues to deliver tangible value to study sponsors. We are very excited to formalize what has been a mutually beneficial collaborative effort over the past few years. We take great pride in our commitment to strong business partnerships that deliver real value to both sides and especially to sponsors. With our ongoing innovation around ePRO technology and the growing demand for our PRO consulting services, we see a nice fit into Quintiles’ approach to serving customers, and we view this relationship as a key step in driving the ePRO market forward,” commented Doug Engfer, co-founder and CEO of invivodata.

About Quintiles
Quintiles is the only fully integrated biopharmaceutical services company offering clinical, commercial, consulting and capital solutions worldwide. The Quintiles network of 23,000 engaged professionals in more than 50 countries around the globe works with an unwavering commitment to patients, safety and ethics. Quintiles helps biopharmaceutical companies navigate risk and seize opportunities in an environment where change is constant. For more information, please visit www.quintiles.com.

About invivodata inc.
invivodata combines behavioral science, information technology and clinical research expertise to capture high quality clinical trial data directly from patients. invivodata’s electronic Patient Reported Outcomes (ePRO) solutions, which are based on over 20 years of research, deliver reliable patient self-reported data by driving patient compliance with the protocol and eliminating recall biases that plague paper-based self-report data. invivodata’s solutions include comprehensive trial-support services that facilitate the collection of ePRO data, web-based access to study data and operational reports that give researchers and sponsors visibility into study progress, and scientific and regulatory consulting on the use of PRO data in a regulated environment. invivodata’s solution has been used in more than 275 clinical programs and is the industry-leading ePRO system in delivering primary efficacy data for FDA drug approvals. invivodata inc. is a privately held company with global headquarters in Pittsburgh, Pa., USA; its European headquarters is in London, England; and its technology development center is in Scotts Valley, Calif., USA. For more information visit www.invivodata.com.

# # #

Read the full story at http://www.prweb.com/releases/2010/01/prweb3455444.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved

Related biology technology :

1. Quintiles Recognized Among Best Companies to Work For in Brazil
2. Quintiles Expands Base for Growing Asia-Pacific Operations
3. Quintiles Named to Computerworld Magazines 100 Best Places to Work in Information Technology List
4. Quintiles Appoints New Executives
5. Quintiles Appoints Christopher Cabell to Chief Medical and Scientific Officer
6. Quintiles Signs Agreement to Acquire Eidetics
7. Quintiles Consulting Business Expands
8. Quintiles Completes Previously Announced New Investor Partnership, Co-Led by Founder, Chairman and CEO Dennis Gillings, Bain Capital, TPG and 3i
9. Quintiles to Open Clinical Research Office in Wilmington, NC
10. Quintiles Central Lab, Clinical Development in China to Expand, Relocate to New Facility
11. Quintiles Names Kelly McKee Executive Director of Operations for Public Health and Government Services Unit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016   Boston Biomedical ... novel compounds designed to target cancer stemness pathways, ... been granted Orphan Drug Designation from the U.S. ... of gastric cancer, including gastroesophageal junction (GEJ) cancer. ... designed to inhibit cancer stemness pathways by targeting ...
(Date:6/23/2016)... Prostate Cancer Foundation (PCF) is pleased to announce 24 new Young ... cancer. Members of the Class of 2016 were selected from a pool of ... More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... , ... June 23, 2016 , ... In a new ... in Denmark detail how a patient who developed lymphedema after being treated for breast ... results could change the paradigm for dealing with this debilitating, frequent side effect of ...
(Date:6/23/2016)... ... 23, 2016 , ... ClinCapture, the only free validated electronic ... showcase its product’s latest features from June 26 to June 30, 2016 for ... Disrupting Clinical Trials in The Cloud during the conference. DIA (Drug Information ...
Breaking Biology Technology:
(Date:4/19/2016)... , UAE, April 20, 2016 ... be implemented as a compact web-based "all-in-one" system solution ... the biometric fingerprint reader or the door interface with ... of modern access control systems. The minimal dimensions of ... ID readers into the building installations offer considerable freedom ...
(Date:4/14/2016)... 14, 2016 BioCatch ™, ... today announced the appointment of Eyal Goldwerger ... Goldwerger,s leadership appointment comes at a time ... the deployment of its platform at several of the ... which discerns unique cognitive and physiological factors, is a ...
(Date:3/31/2016)... March 31, 2016  Genomics firm Nabsys has completed ... Barrett Bready , M.D., who returned to the ... original technical leadership team, including Chief Technology Officer, ... Development, Steve Nurnberg and Vice President of Software and ... company. Dr. Bready served as CEO of ...
Breaking Biology News(10 mins):